Brivaracetam: what does this study show?
Nine patients completed the crossover trial: intravenous brivaracetam 100 mg versus levetiracetam 1,500 mg, using 5- or 15-minute infusions.
Median response-suppression times were 2 versus 7.5 minutes. Combined analysis favored brivaracetam, but the two separate infusion-duration comparisons were nonsignificant.
The authors call for clinical-outcome studies. This does not demonstrate superior cognition or long-term seizure control.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The authors call for clinical-outcome studies. This does not demonstrate superior cognition or long-term seizure control.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.